NovoCure Limited
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $655.4M | $605.2M | $509.3M | $537.8M | $535.0M | $494.4M | $351.3M | $248.1M |
| Cost of Revenue | $166.9M | $137.2M | $128.3M | $114.9M | $114.9M | $106.5M | $88.6M | $80.0M |
| Gross Profit | $488.5M | $468.0M | $381.1M | $423.0M | $420.2M | $387.9M | $262.7M | $168.0M |
| Gross Margin | 74.5% | 77.3% | 74.8% | 78.6% | 78.5% | 78.5% | 74.8% | 67.7% |
| Operating Expenses | ||||||||
| Research & Development | $224.5M | $209.6M | $223.1M | $206.1M | $201.3M | $132.0M | $79.0M | $50.6M |
| SG&A Expense | $177.7M | $189.8M | $164.1M | $132.8M | $126.1M | $107.4M | $87.9M | $73.5M |
| Operating Income | $-153.8M | $-170.5M | $-232.9M | $-89.5M | $-44.3M | $30.4M | $-914.0K | $-33.7M |
| Operating Margin | -23.5% | -28.2% | -45.7% | -16.6% | -8.3% | 6.1% | -0.3% | -13.6% |
| Interest Expense | $22.2M | $11.7M | $4.9M | $8.1M | $8.8M | $18.1M | $14.6M | $16.9M |
| Pretax Income | $-136.3M | $-131.2M | $-191.7M | $-81.8M | $-52.1M | $18.1M | $-8.8M | $-45.9M |
| Income Tax Expense | $-23.0K | $37.5M | $15.3M | $10.7M | $6.3M | $-1.7M | $-1.6M | $17.6M |
| Net Income | $-136.2M | $-168.6M | $-207.0M | $-92.5M | $-58.4M | $19.8M | $-7.2M | $-63.6M |
| Net Margin | -20.8% | -27.9% | -40.6% | -17.2% | -10.9% | 4.0% | -2.1% | -25.6% |
| EPS (Basic) | $-1.22 | $-1.56 | $-1.95 | $-0.88 | $-0.56 | $0.20 | $-0.07 | $-0.69 |
| EPS (Diluted) | $-1.22 | $-1.56 | $-1.95 | $-0.88 | $-0.56 | $0.18 | $-0.07 | $-0.69 |
| Shares Outstanding (Basic) | 111.5M | 107.8M | 106.4M | 104.7M | 103.4M | 100.9M | 97.2M | 91.8M |
| Shares Outstanding (Diluted) | 111.5M | 107.8M | 106.4M | 104.7M | 103.4M | 108.9M | 97.2M | 91.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |